Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DFine's radiofrequency ablation system gets FDA nod

This article was originally published in Clinica

Executive Summary

A new percutaneous radiofrequency ablation system developed by DFine has received 510(k) approval from the US FDA. The product is intended for the palliative treatment of cancer patients with spinal metastases. These lesions affect over 400,000 patients per year worldwide, causing severe pain and discomfort. Current treatments include narcotics and external beam radiation, which can take "weeks or months" to work, according to DFine. Patients may also need to stop receiving chemotherapy for their primary cancer because of cumulative toxicity. Targeted radiofrequency ablation can provide immediate pain relief, improving patients' quality of life, the San Jose, California-based firm says. The technique is also used to treat liver, lung and kidney cancers, using heat produced by radio waves to destroy cancer cells.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts